A phylodynamic analysis combining Arizona wild bird surveillance with national sequence data found the H5N1 D1.1 genotype spread in a stepwise pattern among adjacent US flyways during fall 2024, with limited direct exchange between the Pacific and Atlantic flyways.
A serologic study of patients in northwestern Italy found hantavirus antibodies in 7.3% of samples tested, with neutralization data suggesting Puumala virus as the likely infecting strain in a region where rodent-borne viral infections are rarely diagnosed.
A real-world analysis of the OPERA cohort found no HIV infections among 315 women using long-acting cabotegravir for PrEP, despite frequent short delays in maintenance injections, reinforcing the regimen's real-world effectiveness.
Week 96 data from the LATA trial show Cabenuva was superior to daily oral therapy in adolescents with HIV, while new real-world OPERA cohort data reinforce comparable effectiveness in adults, both presented at AIDS 2026.
An oral antiviral candidate blocked airborne and direct-contact transmission of a measles-like virus in ferrets, offering a potential new outbreak-control tool as US measles cases hit a 35-year high.
Atea Pharmaceuticals' bemnifosbuvir/ruzasvir combination met its primary endpoint of noninferiority to sofosbuvir/velpatasvir in the phase 3 C-BEYOND trial, achieving comparable cure rates for hepatitis C with as little as 8 weeks of treatment.
2026 clinical practice guidelines developed by the IDSA and ESCMID address risk stratification, diagnosis and management of S aureus bacteremia.
Several combination products are currently in development for people with HIV. Here is a review of these treatments.
Despite competing national crises drawing attention elsewhere, experts warn that the ongoing H5N1 avian influenza outbreak in birds, cattle, and humans in the United States highlights critical gaps in surveillance, worker protections, and pandemic preparedness that must be addressed to prevent a future pandemic.
FDA's acting deputy commissioner for food said the US food supply remains safe even as CDC-confirmed cyclosporiasis cases climbed past 11,000, while a new survey found nearly half of Americans don't trust the agency to manage the outbreak.
Sharon Nachman, MD, chief of pediatric infectious disease at Stony Brook Children's Hospital, explains why local resistance data, not just global forecasts, should drive today's empiric antibiotic choices in children.
A global surveillance study of more than 100,000 pediatric bacterial isolates found rising antimicrobial resistance across all regions from 2004 to 2022, with forecasts projecting continued increases in resistance to last-line antibiotics through 2035.
A Rutgers Health study in Health Affairs found substantial growth in long-acting injectable buprenorphine prescriptions for opioid use disorder from 2021 to 2024, but with sharp state-level disparities driven by Medicaid policy differences, with fewer than 1% of buprenorphine prescribed as injectable in some states versus nearly 13% in others.
Shionogi's XOCOVA (ensitrelvir) is now available in the United States as the first oral option to help prevent COVID-19 after exposure, following phase 3 SCORPIO-PEP trial data showing a 67% reduction in symptomatic infection risk.
Three concurrent studies identify T cell exhaustion and Th2 skewing as distinct immune phenotypes in disseminated coccidioidomycosis, with targeted immunomodulation producing dramatic clinical responses in patients who had failed standard antifungal therapy.
ViiV Healthcare's 2-drug Dovato regimen met its noninferiority end point against Gilead's 3-drug Biktarvy in the first head-to-head randomized trial comparing the 2 in treatment-naive adults with HIV.
As the Cyclospora outbreak continues, clinicians and public health advocates are highlighting a secondary risk: antibiotic treatment for the parasitic infection can disrupt the gut microbiome and raise the risk of C diff.
A study of 87 free-roaming New York City cats found 57.5% harbored at least 1 zoonotic endoparasite, with young male cats identified as Toxocara super-shedders depositing disproportionately high concentrations of roundworm eggs into urban soil.
A study in the American Journal of Physiology identifies retrotrapezoid nucleus (RTN) neurons as a critical and preserved circuit for counteracting opioid-induced respiratory depression, with optogenetic and chemogenetic stimulation of RTN neurons restoring breathing even during fentanyl administration.
Histoplasmosis is a widely distributed and often underdiagnosed fungal infection that can cause severe, sometimes fatal disease—especially in immunocompromised patients—due largely to persistent diagnostic delays and limited routine testing. Here is a review of diagnostics and treatment for the fungal infection.
The US has confirmed more measles cases in 2026 than in any year since 1991, with CDC and Johns Hopkins trackers both surpassing 2025's full-year total 5 months before year's end.
CDC's confirmed case count for the Cyclospora outbreak linked to Taylor Farms de Mexico lettuce has topped 4000 as FDA opens a second, separate outbreak investigation and lawmakers press for restored FoodNet surveillance.
Zoliflodacin has exhibited low cross-resistance with FQ-resistant and ceftriaxone- and azithromycinresistant in strains of N gonorrhoeae around the world. Here is a review of this recently approved antibiotic.
Basecamp Research's EDEN AI model, now integrated with Claude Science, designed antibiotic peptides active against 97% of WHO priority pathogens in lab tests, including MDR Acinetobacter baumannii, and can reduce vaccine target prioritization from weeks to a single AI conversation.
A multicenter retrospective study found that the DENOVi clinical prediction score can safely help rule out infective endocarditis in patients with enterococcal bacteremia while reducing unnecessary echocardiography.
The FDA has granted EUA for the Allplex HSV-1&2/VZV/MPXV Assay (Seegene USA), the first multiplex PCR test designed to simultaneously differentiate HSV-1, HSV-2, VZV, and mpox virus from ulcerative skin lesions in a single run.
A study found that the investigational antiviral mosnodenvir reduced dengue virus infection RNA levels and symptoms in a controlled setting, supporting its potential as a prophylactic option.
Phase 3 ISLEND-1 and ISLEND-2 trials showed once-weekly oral islatravir/lenacapavir was noninferior to daily BIKTARVY and standard of care ART in maintaining virologic suppression at Week 48, with no new safety concerns identified.
A large platform trial evaluates diverse medications to relieve fatigue persisting post-acute COVID-19.
Although there has been conflicting public information around whether the source of the outbreak has been determined, Catherine O’Neal, MD, offers insights on key symptoms that warrant medical evaluation, what medical treatment may consist of for those being seen in an outpatient setting or those who are hospitalized, and considerations around eating produce.
